| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/26/2004 | WO2004071462A2 Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction |
| 08/26/2004 | WO2004071461A2 Tra16 a tr4/tr2 repressor |
| 08/26/2004 | WO2004071458A2 REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS |
| 08/26/2004 | WO2004071457A2 Improved heat shock protein-based vaccines and immunotherapies |
| 08/26/2004 | WO2004071441A2 Compositions and methods to modulate immune and inflammatory responses |
| 08/26/2004 | WO2004071436A2 The use of gcc ligands |
| 08/26/2004 | WO2004071429A2 Lung inflammation treatment |
| 08/26/2004 | WO2004071420A2 Compositions and methods for less immunogenic protein formulations |
| 08/26/2004 | WO2004071418A2 Compounds for the treatment of systemic lupus erythematosus |
| 08/26/2004 | WO2004071416A2 Novel inhibitors of formation of advanced glycation endproducts (ages) |
| 08/26/2004 | WO2004071415A2 Method for treating elevated intraocular pressure, including glaucoma |
| 08/26/2004 | WO2004071414A2 Therapeutic anti-hcv (al9) compounds |
| 08/26/2004 | WO2004071413A2 Method and composition for potentiating an opiate analgesic |
| 08/26/2004 | WO2004071411A2 Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620 |
| 08/26/2004 | WO2004071407A2 Antisense modulation of ptp1b expression |
| 08/26/2004 | WO2004071405A2 Lactate dehydrogenase: a target and reagent for diabetes therapy |
| 08/26/2004 | WO2004071392A2 Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4) |
| 08/26/2004 | WO2004071378A2 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a) |
| 08/26/2004 | WO2004071218A2 Preparation and food product comprising an active phytase |
| 08/26/2004 | WO2004058324A3 Antithrombotic venous access devices and methods |
| 08/26/2004 | WO2004056991A3 Novel angiogenic molecular target and uses thereof |
| 08/26/2004 | WO2004052236A3 Methods and compositions for treatment of otitis media |
| 08/26/2004 | WO2004050907A3 Method for determing predisposition to manifestation of immune system related diseases |
| 08/26/2004 | WO2004045555A3 Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2 |
| 08/26/2004 | WO2004045392A3 Diagnostic method for celiac sprue |
| 08/26/2004 | WO2004044163A9 Methods for identifying risk of melanoma and treatments thereof |
| 08/26/2004 | WO2004041153A3 Pharmaceutical composition including low dosages of desmopressin |
| 08/26/2004 | WO2004039834A3 Recombinant protein variants |
| 08/26/2004 | WO2004035755A3 Transporters and ion channels |
| 08/26/2004 | WO2004035609A3 Use of poly-alpha2,8-sialic acid mimetic peptides to modulate ncam functions. |
| 08/26/2004 | WO2004031356A3 Recombinant intracellular pathogen immunogenic compositions and methods for use |
| 08/26/2004 | WO2004030687A8 Long-acting gonadotropin-releasing hormone analogs and methods of use thereof |
| 08/26/2004 | WO2004028465A3 Hemostatic compositions and methods |
| 08/26/2004 | WO2004026909A3 Method of treating rheumatoid arthritis by interfering with expression of dc-sign by macrophages and diagnosis thereof |
| 08/26/2004 | WO2004024092A3 Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| 08/26/2004 | WO2004018706A3 A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish |
| 08/26/2004 | WO2004018684A3 T-cell epitopes in staphylococcal enterotoxin b |
| 08/26/2004 | WO2004016749A3 Antisense modulation of acyl-coa synthetase 1 expression |
| 08/26/2004 | WO2004011615A3 USES OF CIRCADIAN GENE mPER2 |
| 08/26/2004 | WO2004009018A3 Antisense modulation of ptprm expression |
| 08/26/2004 | WO2004004653A3 Methods for treating psychosis associated with interferon-alpha therapy |
| 08/26/2004 | WO2004000207A3 Toxin-phage bacteriocide antibiotic and uses thereof |
| 08/26/2004 | WO2003101402A3 Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| 08/26/2004 | WO2003099833A3 Beta-2-glycoprotein 1 is an inhibitor of angiogenesis |
| 08/26/2004 | WO2003094965A8 Modulation of neural stem cells with s1p or lpa receptor agonists |
| 08/26/2004 | WO2003092602A3 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 08/26/2004 | WO2003088905A3 Compositions and minimally invasive methods for treating incomplete tissue repair |
| 08/26/2004 | WO2003087320A3 Antagonists of il-21 and modulation of il-21-mediated t cell responses |
| 08/26/2004 | WO2003070911A3 Rna interference mediated inhibition of type 1 insulin-like growth factor receptor (igf-1r) |
| 08/26/2004 | WO2003070823A3 Conjugates comprising a biodegradable polymer and uses therefor |
| 08/26/2004 | WO2003055440A3 Compositions and methods for the treatement of immune related diseases |
| 08/26/2004 | WO2003046147A3 Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof |
| 08/26/2004 | WO2002102320A3 Fce fusion proteins for treatment of allergy and asthma |
| 08/26/2004 | WO2002085302A3 Methods of treating intestinal inflammation |
| 08/26/2004 | WO2001051003A3 Use of lipid conjugates in the treatment of disease |
| 08/26/2004 | US20040167337 Boron compounds such as R)-1-{(S)-2-[(S)-2-(biphenyl-3-ylamino)-(3-(3,4,5-trimethoxy-phenyl)-propionylamino]-3-methyl-butyrylamino}-3-methyl-butylboronic acid, used as antitumor or antiproliferative agents |
| 08/26/2004 | US20040167332 Boronic ester and acid compounds, synthesis and uses |
| 08/26/2004 | US20040167330 Suitable targeting moieties are monoclonal antibodies, their fragments and recombinant derivatives such as single chain antibodies, diabodies, triabodies, humanized, human or chimeric variants but also peptides, aptamers, spiegelmers, nucleotides, anti sense oligomers |
| 08/26/2004 | US20040167318 comprising treating the collagen-containing portion with a weak acid solution in order to solubilize and collect the collagen-derived protein fraction; for drugs/cosmetics/foods |
| 08/26/2004 | US20040167317 for treating lymphocyte-related disorders using self-assembling molecular complex designated pre-pro-B cell growth stimulating factor (PPBSF); genetic engineering |
| 08/26/2004 | US20040167201 Pyrrolidine melanocortin-specific compounds |
| 08/26/2004 | US20040167191 Glutaminyl based DPIV inhibitors |
| 08/26/2004 | US20040167160 Skin disorders; controlling cell differentiation; antidiabetic agents; cardiovascular disorders; anticancer agents; central nervous system disorders |
| 08/26/2004 | US20040167140 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides |
| 08/26/2004 | US20040167116 Viricides |
| 08/26/2004 | US20040167108 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 08/26/2004 | US20040167078 Agents for improving lipid metabolism and reducing high blood pressure |
| 08/26/2004 | US20040167076 Vision defects screening; using antibody; measure increase in hydraulic conductivity, electrical resistance as indicator of cadherin inhibition |
| 08/26/2004 | US20040167075 Diagnosis, therapy od Alzheimer's disease; blocking psychological conditions |
| 08/26/2004 | US20040167074 Therapeutic applications of mFLINT polypeptides |
| 08/26/2004 | US20040167073 derived the N-terminus of the alpha S1 fraction of milk casein; stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis; treating hypercholesterolemia, hematological disorders and viral-related diseases |
| 08/26/2004 | US20040167072 Inhibitors of receptor activator of NF-kappaB and uses thereof |
| 08/26/2004 | US20040167071 treating with a solution of base at a pH of 10-13 to inactivate prions in a manner that does not adversely affect the biological activity; removing prions from a lipoprotein solution by contacting with an adsorbant that binds more tightly to the lipoprotein than to the prion, such as silica |
| 08/26/2004 | US20040167070 Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease |
| 08/26/2004 | US20040167069 administering a transglutaminase inhibitor, particularly a compound with a 3-halo-dihydroisoxazole moiety or an analog of isatin, to attenuate gluten toxicity |
| 08/26/2004 | US20040167067 ESM-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same |
| 08/26/2004 | US20040167066 Cleavage and polyadenylation complex of precursor mrna |
| 08/26/2004 | US20040167065 human transferases and polynucleotides which identify and encode them; expression vectors, host cells, antibodies, agonists, and antagonists; diagnosing, treating, or preventing disorders associated with aberrant expression of the transferases |
| 08/26/2004 | US20040167064 Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| 08/26/2004 | US20040167063 fatty acid triglyceride and a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, e.g., transesterification product of a vegetable oil with glycerol, propylene glycol or sorbitol |
| 08/26/2004 | US20040167060 Inhibitor and stimulator of stem cell proliferation and uses thereof |
| 08/26/2004 | US20040166565 for treating diseases relating to angiogenesis; fusion protein possesses ribosome inactivating activity and ability to bind to cellular vascular endothelial growth factor (VEGF) receptors |
| 08/26/2004 | US20040166543 Regulation of cell growth by MUC1 |
| 08/26/2004 | US20040166530 F-box proteins and genes |
| 08/26/2004 | US20040166497 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 08/26/2004 | US20040166490 Comprises nucleotide sequences coding cancer associated protein (CA protein) for use in diagnosis, prevention and treatment of cell proliferative disorders |
| 08/26/2004 | US20040166198 Therapy, prevention of diarrhea; side effect reduction; fermentation of plant material with fungi |
| 08/26/2004 | US20040166183 Methods and means for preventing or treating inflammation or pruritis |
| 08/26/2004 | US20040166181 Mixture of soybean protein and chromium |
| 08/26/2004 | US20040166176 Side effect reduction; reducing pain; synergistic mixture containing muscle relaxants; administering prostaglandins |
| 08/26/2004 | US20040166175 Compositions and methods for nutrition supplementation |
| 08/26/2004 | US20040166150 Mixture of expression vector for antihemophilic factor and lipid |
| 08/26/2004 | US20040166119 Prevention and treatment of amyloidogenic disease |
| 08/26/2004 | US20040166114 Remedies for interstitial pneumonia, method of preparing animal model of said disease, and screening method using the same |
| 08/26/2004 | US20040166113 Administering interleukin inhibitor |
| 08/26/2004 | US20040166112 Administering interleukin inhibitors |
| 08/26/2004 | US20040166110 For multiple drug resistance cancer; purification of hemoatopoietic stem cells; diagnosis, therapy |
| 08/26/2004 | US20040166109 Modulator polypeptide for regulation of intracellular endocytosis of amyloid precursor proteins; diagnosis and treatment of neurodegenerative disorders |
| 08/26/2004 | US20040166105 Compositions and methods relating to breast specific genes and proteins |
| 08/26/2004 | US20040166104 Viricides, antiprotozoa agents, parasiticides using venom |